EMBCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends September 30
Embecta Corp.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.21−0.06 (-0.96%)
Close on Oct 19, 2026
- Market cap
- $363.36M
- P/E (TTM)
- 4.2
- Dividend yield
- 9.66%
Share price
−$7.35 (−54.20%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
Embecta Corp. saw revenue fall 7.6% to $1.02B over the twelve months to Jun 30, 2026. Operating income rose 5.5% to $223.50M, moving the operating margin from 19.2% to 21.9%. Free cash flow was $164.60M, up 24.4% from a year earlier.
Revenue
$1.02B
-7.6% vs. a year earlier
Operating income
$223.50M
+5.5% vs. a year earlier
Free cash flow
$164.60M
+24.4% vs. a year earlier
EPS, diluted
$1.47
+2.8% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $363.36M
- P/E ratio
- 4.2
- Price to sales
- 0.36
- Price to book
- –
- Dividend yield
- 9.66%
- Free cash flow yield
- 45.30%
Fundamentals
- Revenue
- $1.02B
- Net income
- $87.50M
- EPS, diluted
- $1.47
- Free cash flow
- $164.60M
- Book value per share
- -$10.47
- Diluted shares
- 59M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$1.02B-7.6% YoY
Gross profit
$601.30M-13.1% YoY
Operating income
$223.50M+5.5% YoY
Net income
$87.50M+4.7% YoY
EPS, diluted
$1.47+2.8% YoY
Free cash flow
$164.60M+24.4% YoY
Reported periodTrailing twelve months